These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 34960125)

  • 41. Immunogenicity and clinical features relating to BNT162b2 messenger RNA COVID-19 vaccine, Ad26.COV2.S and ChAdOx1 adenoviral vector COVID-19 vaccines: a systematic review of non-interventional studies.
    Iheanacho CO; Eze UIH
    Futur J Pharm Sci; 2022; 8(1):20. PubMed ID: 35368622
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Induction of SARS-CoV-2-Specific IgG and IgA in Serum and Milk with Different SARS-CoV-2 Vaccines in Breastfeeding Women: A Cross-Sectional Study in Northern Spain.
    Lechosa-Muñiz C; Paz-Zulueta M; Mendez-Legaza JM; Irure-Ventura J; Cuesta González R; Calvo Montes J; López-Hoyos M; Llorca J; Cabero-Pérez MJ
    Int J Environ Res Public Health; 2021 Aug; 18(16):. PubMed ID: 34444579
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines.
    Marking U; Havervall S; Greilert-Norin N; Ng H; Blom K; Nilsson P; Phillipson M; Hober S; Nilsson C; Mangsbo S; Christ W; Klingström J; Gordon M; Åberg M; Thålin C
    Vaccines (Basel); 2022 Feb; 10(3):. PubMed ID: 35334989
    [TBL] [Abstract][Full Text] [Related]  

  • 44. SARS-CoV-2 Antibody Response to the BNT162b2 mRNA Vaccine in Persons with Past Natural Infection.
    Kang YM; Choe KW; Lee KD; Kim KN; Kim MJ; Lim J
    J Korean Med Sci; 2021 Sep; 36(35):e250. PubMed ID: 34490757
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Influence of past infection with SARS-CoV-2 on the response to the BNT162b2 mRNA vaccine in health care workers: Kinetics and durability of the humoral immune response.
    Ontañón J; Blas J; de Cabo C; Santos C; Ruiz-Escribano E; García A; Marín L; Sáez L; Beato JL; Rada R; Navarro L; Sainz de Baranda C; Solera J
    EBioMedicine; 2021 Nov; 73():103656. PubMed ID: 34740112
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of safety and immunogenicity of CoronaVac and ChAdOx1 against the SARS-CoV-2 circulating variants of concern (Alpha, Delta, Beta) in Thai healthcare workers.
    Angkasekwinai N; Sewatanon J; Niyomnaitham S; Phumiamorn S; Sukapirom K; Sapsutthipas S; Sirijatuphat R; Wittawatmongkol O; Senawong S; Mahasirimongkol S; Trisiriwanich S; Chokephaibulkit K
    Vaccine X; 2022 Apr; 10():100153. PubMed ID: 35282410
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety and tolerability of the novel 2019 coronavirus disease (COVID-19) vaccines among people with epilepsy (PwE): A cross-sectional study.
    Massoud F; Ahmad SF; Hassan AM; Alexander KJ; Al-Hashel J; Arabi M
    Seizure; 2021 Nov; 92():2-9. PubMed ID: 34391030
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Waning of Anti-spike Antibodies in AZD1222 (ChAdOx1) Vaccinated Healthcare Providers: A Prospective Longitudinal Study.
    Mishra SK; Pradhan SK; Pati S; Sahu S; Nanda RK
    Cureus; 2021 Nov; 13(11):e19879. PubMed ID: 34976499
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Reduced Titers of Circulating Anti-SARS-CoV-2 Antibodies and Risk of COVID-19 Infection in Healthcare Workers during the Nine Months after Immunization with the BNT162b2 mRNA Vaccine.
    Coppeta L; Ferrari C; Somma G; Mazza A; D'Ancona U; Marcuccilli F; Grelli S; Aurilio MT; Pietroiusti A; Magrini A; Rizza S
    Vaccines (Basel); 2022 Jan; 10(2):. PubMed ID: 35214600
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Neutralizing Anti-SARS-CoV-2 Antibody Titer and Reported Adverse Effects, in a Sample of Italian Nursing Home Personnel after Two Doses of the BNT162b2 Vaccine Administered Four Weeks Apart.
    Modenese A; Paduano S; Bargellini A; Bellucci R; Marchetti S; Bruno F; Grazioli P; Vivoli R; Gobba F
    Vaccines (Basel); 2021 Jun; 9(6):. PubMed ID: 34203652
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial.
    Folegatti PM; Bittaye M; Flaxman A; Lopez FR; Bellamy D; Kupke A; Mair C; Makinson R; Sheridan J; Rohde C; Halwe S; Jeong Y; Park YS; Kim JO; Song M; Boyd A; Tran N; Silman D; Poulton I; Datoo M; Marshall J; Themistocleous Y; Lawrie A; Roberts R; Berrie E; Becker S; Lambe T; Hill A; Ewer K; Gilbert S
    Lancet Infect Dis; 2020 Jul; 20(7):816-826. PubMed ID: 32325038
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety, immunogenicity & effectiveness of the COVID-19 vaccine among healthcare workers in a tertiary care hospital.
    Kataria S; Sharma P; Singh MK; Deswal V; Kumar K; Alam S; Gupta V; Phogat R; Sarma S; Patil N; Dutt R; Singh P; Saxena R; Trehan N
    Indian J Med Res; 2022; 155(5&6):518-525. PubMed ID: 36348600
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of S1RBD-Specific IgG Antibody Responses following COVID-19 Vaccination in Healthcare Professionals in Cyprus: A Comparative Look between the Vaccines of Pfizer-BioNTech and AstraZeneca.
    Deeba E; Krashias G; Constantinou A; Koptides D; Lambrianides A; Christodoulou C
    Microorganisms; 2022 May; 10(5):. PubMed ID: 35630412
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Reactogenicity and Immunogenicity of the ChAdOx1 nCOV-19 Coronavirus Disease 2019 Vaccine in South Korean Healthcare Workers.
    Hyun J; Park Y; Song YG; Han SH; Park SY; Kim SH; Park JS; Jeon SY; Lee HS; Lee KH
    Yonsei Med J; 2022 Dec; 63(12):1078-1087. PubMed ID: 36444543
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effectiveness of Comirnaty
    Fernández-Lázaro D; Garrosa M; Sánchez-Serrano N; Garrosa E; Jiménez-Callejo E; Pardo Yanguas MD; Mielgo-Ayuso J; Seco-Calvo J
    Vaccines (Basel); 2022 Jul; 10(8):. PubMed ID: 35893819
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety Following COVID-19 Booster Vaccine with BNT162b2 Compared to mRNA-1273 in Solid Cancer Patients Previously Vaccinated with ChAdOx1 or CoronaVac.
    Wanchaijiraboon P; Sainamthip P; Teeyapun N; Luangdilok S; Poovorawan Y; Wanlapakorn N; Tanasanvimon S; Sriuranpong V; Susiriwatananont T; Zungsontiporn N; Pakvisal N
    Vaccines (Basel); 2023 Feb; 11(2):. PubMed ID: 36851234
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Initial observations on age, gender, BMI and hypertension in antibody responses to SARS-CoV-2 BNT162b2 vaccine.
    Pellini R; Venuti A; Pimpinelli F; Abril E; Blandino G; Campo F; Conti L; De Virgilio A; De Marco F; Di Domenico EG; Di Bella O; Di Martino S; Ensoli F; Giannarelli D; Mandoj C; Manciocco V; Marchesi P; Mazzola F; Moretto S; Petruzzi G; Petrone F; Pichi B; Pontone M; Zocchi J; Vidiri A; Vujovic B; Piaggio G; Morrone A; Ciliberto G
    EClinicalMedicine; 2021 Jun; 36():100928. PubMed ID: 34109307
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222.
    Terpos E; Karalis V; Ntanasis-Stathopoulos I; Evangelakou Z; Gavriatopoulou M; Manola MS; Malandrakis P; Gianniou DD; Kastritis E; Trougakos IP; Dimopoulos MA
    Biomedicines; 2022 Feb; 10(2):. PubMed ID: 35203547
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2.
    Reiter R; Von Blanckenburg P; Mutters R; Thiemer J; Geßner R; Seifart U
    Vaccines (Basel); 2022 May; 10(5):. PubMed ID: 35632544
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer.
    Goshen-Lago T; Waldhorn I; Holland R; Szwarcwort-Cohen M; Reiner-Benaim A; Shachor-Meyouhas Y; Hussein K; Fahoum L; Baruch M; Peer A; Reiter Y; Almog R; Halberthal M; Ben-Aharon I
    JAMA Oncol; 2021 Oct; 7(10):1507-1513. PubMed ID: 34236381
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.